Filing summary
Important identity and period clarification: The supplied filing is TenX Keane Acquisition’s unaudited Form 10-Q for the quarter ended March 31, 2024—not a Citius Oncology, Inc. 10-Q for 2024 Q2. TenX was a SPAC seeking to combine with Citius Oncology; its results do not report Citius Oncology’s operating performance.
Business context and reporting period
TenX had no operating business or revenue as of March 31, 2024. Its activity concerned its formation, public offering, and search for a business combination. The financial statements compare the three months ended March 31, 2024 and 2023.
TenX had agreed to combine with Citius Oncology. The proposed transaction contemplated Citius Pharma receiving 67.5 million shares valued at an implied $675 million, contributing $10 million cash, and the combined company assuming 12.6 million existing options. Closing remained subject to shareholder approval and other conditions.
Financial results and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None | None |
| General and administrative costs | $268,429 | $147,922 |
| Trust investment interest income | $758,258 | $759,647 |
| Net income | $489,829 | $611,725 |
| Net income per share | $0.07 | $0.07 |
| Operating cash used | $191,690 | $168,799 |
Net income fell about 20% year over year as expenses rose while trust interest income was nearly unchanged. No operating margin is meaningful because TenX had no revenue.
At March 31, 2024, total assets were $48.7 million, including $48.6 million held in trust; cash outside the trust was only $33,330. Current liabilities were $2.8 million, including a $1.52 million sponsor note, $537,149 due to a related party, and $268,645 due to shareholders. Redeemable shares were recorded as $48.3 million of temporary equity, and shareholders’ deficit was $2.46 million. No conventional interest-bearing debt balance is separately reported; the sponsor and extension notes are described as non-interest-bearing.
Trust investments fell from $72.6 million at December 31, 2023, primarily reflecting $24.9 million paid for share redemptions. The company reported a $584 increase in cash for the quarter: $24.7 million investing inflows were largely offset by $24.5 million financing outflows, including redemption payments.
Material changes, outlook, and risks
- Shareholders approved an extension in January 2024, and 2,287,923 shares were redeemed. The filing reports 6,653,077 total ordinary shares outstanding after those redemptions.
- TenX stated that the business-combination deadline was extended to June 18, 2024 through monthly extensions. Citius Pharma made two subsequent $66,667 trust contributions in April and May, each evidenced by a non-interest-bearing note.
- Management disclosed substantial doubt about TenX’s ability to continue as a going concern: available outside-trust cash was inadequate, and failure to complete a combination by the applicable deadline would require redemption of public shares and liquidation. The filing says the financial statements include no adjustments for that uncertainty.
- Management expected further legal, reporting, due-diligence, and transaction costs and said additional financing might be required. It provided no operating-company earnings or revenue guidance.
- Disclosure controls were deemed ineffective because of material weaknesses in accounting for accruals, related-party advances, and complex financial instruments. The filing says the redemption-price calculation for the January meeting requires correction and an additional payment to affected redeemers; the amount is not stated.
- The filing reports no material litigation and no material market or interest-rate exposure as of March 31, 2024. It also describes possible dilution and transaction expenses, including a $500,000 financial-adviser fee payable in equity at a transaction closing.
Key facts for investors to verify
- Confirm the intended issuer and period: this is TenX’s March 31, 2024 quarterly report, not Citius Oncology’s Q2 report.
- Check subsequent filings for whether the proposed merger closed, the final deadline and any liquidation, and the resulting ownership and financing terms.
- Verify the amount, timing, and completion of the required redemption-price adjustment for January redeemers.
- Review TenX’s post-quarter liquidity, sponsor/Citius Pharma advances, and any further redemptions or extension contributions.
- Reconcile share counts and redemption classifications: the filing presents 4,312,077 shares subject to possible redemption at March 31 and separately reports 6,653,077 total shares outstanding after January redemptions.